Market Research Logo

C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Pipeline Review, H1 2016

C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Pipeline Review, H1 2016’, provides in depth analysis on C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) targeted pipeline therapeutics.

The report provides comprehensive information on the C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2)
  • The report reviews C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) Overview
Therapeutics Development
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Products under Development by Stage of Development
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Products under Development by Therapy Area
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Products under Development by Indication
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Pipeline Products Glance
Late Stage Products
Early Stage Products
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Products under Development by Companies
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Products under Development by Universities/Institutes
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Companies Involved in Therapeutics Development
ChemoCentryx, Inc.
Dompe Farmaceutici S.p.A.
GlaxoSmithKline Plc
Novartis AG
Syntrix Biosystems, Inc.
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Drug Profiles
danirixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DF-2755A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ladarixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CXCR2 for Respiratory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAC-G31P - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reparixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-517 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-576 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-682 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Dormant Projects
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Discontinued Products
C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Featured News & Press Releases
Dec 10, 2015: Research presented at the San Antonio Breast Cancer Symposium intended to strike at the heart of cancer stem cells
Oct 01, 2014: Dompe commitment in oncology against cancer stem cells
Sep 25, 2013: Pharmaceutical company Dompé launches REP0112, a trial to assess the efficacy and safety of Reparixin in autologous islet cell transplantation
Jul 10, 2013: Dompé announces innovative treatment in the fight against type 1 diabetes: pancreatic islet cell transplantation, a hope that has already come true
Dec 06, 2012: Dompé Announces Presentation Of Reparixin Clinical Trial Data In Metastatic Breast Cancer At 34th CTRC-AACR San Antonio Breast Cancer Symposium
Oct 23, 2012: Dompé Announces Enrollment Of First Patient In Phase III Trial On Reparixin
Oct 24, 2011: Dompé Announces Presentation Of Phase II Clinical Data Of Reparixin For Improvement Of Efficacy of Pancreatic Islet Transplantation At 2011 CTS-IXA Congress
Oct 13, 2011: Dompé's Reparixin Receives EMA Orphan Drug Designation For Prevention Of Graft Rejection In Pancreatic Islet Transplantation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by ChemoCentryx, Inc., H1 2016
Pipeline by Dompe Farmaceutici S.p.A., H1 2016
Pipeline by GlaxoSmithKline Plc, H1 2016
Pipeline by Novartis AG, H1 2016
Pipeline by Syntrix Biosystems, Inc., H1 2016
Dormant Projects, H1 2016
Dormant Projects (Contd..1), H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report